RELIEF™ trial demonstrated statistically significant reductions in oral ulcers with apremilast 30 mg versus placebo through week 12 Significant improvements in key secondary endpoints, inclu…
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet』s Disease with Oral Ulcers
RELIEF™ trial demonstrated statistically significant reductions in oral ulcers with apremilast 30 mg versus placebo through week 12 Significant improvements in key secondary endpoints, inclu…